Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma

Nature volume 616, pages 806–813 (2023)Cite this article

Subjects

Abstract

Metastasis frequently develops from disseminated cancer cells that remain dormant after the apparently successful treatment of a primary tumour. These cells fluctuate between an immune-evasive quiescent state and a proliferative state liable to immune-mediated elimination1,2,3,4,5,6. Little is known about the clearing of reawakened metastatic cells and how this process could be therapeutically activated to eliminate residual disease in patients. Here we use models of indolent lung adenocarcinoma metastasis to identify cancer cell-intrinsic determinants of immune reactivity during exit from dormancy. Genetic screens of tumour-intrinsic immune regulators identified the stimulator of interferon genes (STING) pathway as a suppressor of metastatic outbreak. STING activity increases in metastatic progenitors that re-enter the cell cycle and is dampened by hypermethylation of the STING promoter and enhancer in breakthrough metastases or by chromatin repression in cells re-entering dormancy in response to TGFβ. STING expression in cancer cells derived from spontaneous metastases suppresses their outgrowth. Systemic treatment of mice with STING agonists eliminates dormant metastasis and prevents spontaneous outbreaks in a T cell- and natural killer cell-dependent manner—these effects require cancer cell STING function. Thus, STING provides a checkpoint against the progression of dormant metastasis and a therapeutically actionable strategy for the prevention of disease relapse.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Genetic screens identify cell-autonomous immune regulators of dormant metastasis.
Fig. 2: STING activation in metastatic progenitors re-entering the cell cycle.
Fig. 3: Metastasis suppression by tumour-intrinsic STING.
Fig. 4: STING downregulation during dormancy and metastatic progression.
Fig. 5: STING-agonist depletion of disseminated cancer cells to prevent metastasis.

Data availability

The raw sequencing data corresponding to CRISPR screens and targeted bisulfite sequencing have been deposited in the NCBI Sequence Read Archive under accessions PRJNA786579 and PRJNA867723, respectively. ChIP–seq data have been deposited in the Gene Expression Omnibus under accession GSE210946. Source data are provided with this paper.

Code availability

Custom code used in this study are available at Zenodo: https://doi.org/10.5281/zenodo.7618821.

References

  1. Goddard, E. T., Bozic, I., Riddell, S. R. & Ghajar, C. M. Dormant tumour cells, their niches and the influence of immunity. Nat. Cell Biol. 20, 1240–1249 (2018).

    Article  CAS  PubMed  Google Scholar 

  2. Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pommier, A. et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science 360, eaao4908 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Pantel, K. et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991).

    CAS  PubMed  Google Scholar 

  5. Eyles, J. et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030–2039 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Massagué, J. & Ganesh, K. Metastasis-initiating cells and ecosystems. Cancer Discov. 11, 971–994 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Consonni, D. et al. Lung cancer prognosis before and after recurrence in a population-based setting. JNCI 107, djv059 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Willis, R. A. The Spread of Tumours in the Human Body (J. & A. Churchill, 1934).

  9. Hadfield, G. The dormant cancer cell. Br. Med. J. 2, 607–610 (1954).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Janni, W. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin. Cancer Res. 17, 2967–2976 (2011).

    Article  PubMed  Google Scholar 

  11. Sosa, M. S., Bragado, P. & Aguirre-Ghiso, J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14, 611–622 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xiao, D. et al. Donor cancer transmission in kidney transplantation: a systematic review. Am. J. Transplant. 13, 2645–2652 (2013).

    Article  CAS  PubMed  Google Scholar 

  13. Laughney, A. M. et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 26, 259–269 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101–104 (2011).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  15. Marcus, A. et al. Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol. 122, 91–128 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116–122 (2010).

    Article  CAS  PubMed  Google Scholar 

  18. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ablasser, A. & Chen, Z. J. cGAS in action: expanding roles in immunity and inflammation. Science 363, eaat8657 (2019).

    Article  CAS  PubMed  Google Scholar 

  20. Chen, Q. et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533, 493–498 (2016).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461–465 (2017).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hong, C. et al. cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature 607, 366–373 (2022).

    Article  ADS  CAS  PubMed  Google Scholar 

  24. Konno, H., Konno, K. & Barber, G. N. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 155, 688–698 (2013).

    Article  CAS  PubMed  Google Scholar 

  25. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chen, H. et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 147, 436–446 (2011).

    Article  CAS  PubMed  Google Scholar 

  27. Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51–62 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Luis-Ravelo, D. et al. Tumor–stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clin. Exp. Metastasis 28, 779–791 (2011).

    Article  CAS  PubMed  Google Scholar 

  29. Jeremiah, N. et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Invest. 124, 5516–5520 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Abe, T. et al. STING recognition of cytoplasmic DNA instigates cellular defense. Mol. Cell 50, 5–15 (2013).

    Article  CAS  PubMed  Google Scholar 

  31. Dufour, J. H. et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168, 3195–3204 (2002).

    Article  CAS  PubMed  Google Scholar 

  32. Appay, V. & Rowland-Jones, S. L. RANTES: a versatile and controversial chemokine. Trends Immunol. 22, 83–87 (2001).

    Article  CAS  PubMed  Google Scholar 

  33. Schutyser, E., Struyf, S. & Van Damme, J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14, 409–426 (2003).

    Article  CAS  PubMed  Google Scholar 

  34. Kitapma, S. et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34–45 (2019).

    Article  Google Scholar 

  35. Bragado, P. et al. TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat. Cell Biol. 15, 1351–1361 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. David, C. J. & Massagué, J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419–435 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Su, J. et al. TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature 577, 566–571 (2020).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  39. Pan, B. S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).

    Article  CAS  PubMed  Google Scholar 

  40. Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Flood, B. A., Higgs, E. F., Li, S. Y., Luke, J. J. & Gajewski, T. F. STING pathway agonism as a cancer therapeutic. Immunol. Rev. 290, 24–38 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466–470 (2017).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chen, J. et al. Cell cycle checkpoints cooperate to suppress DNA- and RNA-associated molecular pattern recognition and anti-tumor immune responses. Cell Rep. 32, 108080 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Deng, L. F. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402–406 (2017).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  47. Gluck, S. et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat. Cell Biol. 19, 1061–1070 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Zierhut, C. et al. The cytoplasmic DNA sensor cGAS promotes mitotic cell death. Cell 178, 302–315.e323 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ahn, J. et al. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 5, 5166 (2014).

    Article  ADS  CAS  PubMed  Google Scholar 

  50. Vasudevan, A. et al. Single-chromosomal gains can function as metastasis suppressors and promoters in colon cancer. Dev. Cell 52, 413–428.e6 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Tello-Lafoz, M. et al. Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. Immunity 54, 1037–1054.e1037 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Girardin, S. E. et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 300, 1584–1587 (2003).

    Article  ADS  CAS  PubMed  Google Scholar 

  54. Wang, Q. et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity 41, 919–933 (2014).

    Article  CAS  PubMed  Google Scholar 

  55. Soto-Feliciano, Y. M. et al. A molecular switch between mammalian MLL complexes dictates response to Menin–MLL inhibition. Cancer Discov. 13, 146–169 (2022).

    Article  PubMed Central  Google Scholar 

  56. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR–Cas9. Nat. Biotechnol. 34, 184–191 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Michlits, G. et al. Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles. Nat. Methods 17, 708–716 (2020).

    Article  CAS  PubMed  Google Scholar 

  58. Sánchez-Rivera, F. J. et al. A base editing sensor streamlines high-throughput guide validation and engineering of cancer associated variants. Nat. Biotechnol. 40, 862–873 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  59. Dow, L. E. et al. Inducible in vivo genome editing with CRISPR–Cas9. Nat. Biotechnol. 33, 390–394 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Minn, A. J. et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44–55 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Ebright, R. Y. et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science 367, 1468–1473 (2020).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  62. Oshimori, N., Oristian, D. & Fuchs, E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963–976 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ahn, J., Gutman, D., Saijo, S. & Barber, G. N. STING manifests self DNA-dependent inflammatory disease. Proc. Natl Acad. Sci. USA 109, 19386–19391 (2012).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  64. Setty, M. et al. Characterization of cell fate probabilities in single-cell data with Palantir. Nat. Biotechnol. 37, 451–460 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at https://arxiv.org/abs/1802.03426 (2018).

  66. Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  67. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  68. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).

    Article  CAS  PubMed  Google Scholar 

  69. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Neri, S., Mariani, E., Meneghetti, A., Cattini, L. & Facchini, A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Diagn. Lab. Immunol. 8, 1131–1135 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Chava, S., Bugide, S., Gupta, R. & Wajapeyee, N. Measurement of natural killer cell-mediated cytotoxicity and migration in the context of hepatic tumor cells. J. Vis. Exp. https://doi.org/10.3791/60714 (2020).

  72. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  74. Karpova, N. N. & Umemori, J. Protocol for methylated DNA immunoprecipitation (MeDIP) analysis. Epigenetic Methods Neurosci. Res. 105, 97–114 (2016).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the Thoracic Oncology Service, the Pathology Core Facility, the Flow Cytometry Core, the Molecular Cytology Core, the Genomic Editing and Screening Core, the Single-cell Analysis Innovation Lab, the Integrated Genomics Operation, and the Research Animal Resource Center at MSKCC for their assistance; the tissue donors at MSKCC for participating in this study; E. Er for early guidance with metastasis assays; C. Rudin for assistance in the procurement of tumour tissue samples; and Z. Zhang, H.-A. Chen and V. Tem for technical assistance. This work was supported by NIH grants R35-CA252978 and P01-CA129243 (J.M.), U54-CA209975 (J.M. and D.P.), K08-CA230213 (K.G.), P30 CA008748 (MSKCC), the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center at MSKCC (J.H., F.J.S.-R., Z.W., K.G., D.P. and J.M.), the Agilent Technologies Thought Leader Award (S.W.L.), and postdoctoral fellowships from the Terri Brodeur Breast Cancer Foundation (J.H.), the Translational Research Oncology Training Program 5T32CA160001 (F.J.S.-R.), and the Damon Runyon Quantitative Biology Program (S.G.). F.J.S.-R. is a HHMI Hanna Gray Fellow. D.P. and S.W.L. are HHMI Investigators.

Author information

Author notes

  1. Francisco J. Sánchez-Rivera

    Present address: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

  2. Francisco J. Sánchez-Rivera

    Present address: Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

Authors and Affiliations

  1. Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jing Hu, Francisco J. Sánchez-Rivera, Zhenghan Wang, Gabriela N. Johnson, Yu-jui Ho, Siting Gan, Jessica P. Hampton, Scott W. Lowe & Joan Massagué

  2. Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Karuna Ganesh

  3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Karuna Ganesh

  4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Shigeaki Umeda & Christine A. Iacobuzio-Donahue

  5. Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Adriana M. Mujal, Rebecca B. Delconte & Joseph C. Sun

  6. Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Huiyong Zhao & Elisa de Stanchina

  7. Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sanjay Kottapalli & Dana Pe’er

  8. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Christine A. Iacobuzio-Donahue

  9. The Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dana Pe’er & Joan Massagué

  10. Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dana Pe’er & Scott W. Lowe

Authors
  1. Jing Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco J. Sánchez-Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhenghan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gabriela N. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-jui Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karuna Ganesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shigeaki Umeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Siting Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adriana M. Mujal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rebecca B. Delconte
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jessica P. Hampton
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Huiyong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sanjay Kottapalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Elisa de Stanchina
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Christine A. Iacobuzio-Donahue
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Dana Pe’er
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Scott W. Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Joseph C. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Joan Massagué
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.H. and J.M. conceived studies, designed experiments, interpreted results and wrote the manuscript. J.H. performed experiments and analysed data. F.J.S.-R., Y.-j.H. and S.W.L. designed and analysed CRISPR screens. S.G., S.K. and D.P. performed scRNA-seq data analysis. G.N.J. and J.P.H. provided technical assistance with experiments. Z.W. generated and characterized TGFβ-reporter and TGFBR2-knockout cell lines and performed immunohistochemistry analysis. K.G. established the KPad1 cell line. K.G., S.U. and C.A.I.-D. procured patient-derived tumour samples and validated the STING immunohistochemistry scoring. A.M.M., R.B.D. and J.C.S. performed immune phenotyping and NK cell cytotoxicity experiments. H.Z. and E.d.S. conducted drug treatment experiments in mice.

Corresponding author

Correspondence to Joan Massagué.

Ethics declarations

Competing interests

S.W.L. received funding and research support from Agilent Technologies for the purposes of massively parallel oligonucleotide synthesis to generate the sgRNA libraries described in this Article.

Peer review

Peer review information

Nature thanks Melanie Werner-Klein and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data figures and tables

Extended Data Fig. 1 In vivo CRISPR screen for cell-autonomous immune regulators of dormant metastasis.

(a) Metastasis-free survival Kaplan-Meier plots of athymic mice intracardially inoculated with 1 x 105 H2030-BrM or H2087-LCC cells. One set of mice inoculated with H2087-LCC cells was treated with anti-asialo-GM1 antibody to deplete NK cells 30 days after cell inoculation. n = 9 (H2030-BrM) or 10 (H2087-LCC) mice per group, log-rank test. (b) Flow cytometry analysis of Lineage–CD45+NKP46+ NK cells in blood from athymic mice that were treated with IgG control or anti-asialo-GM1 antibody for 4 days. Lineage– : TCRβ–CD3–CD19–B220–CD11c–Ly6G–F4/80–. n = 3 mice per group. Mean ± s.e.m., two-sided unpaired t-test. (c) Petal charts of metastasis incidence in specific organs of 10 athymic mice intracardially inoculated with 1x105 H2087-LCC cells, treated with or without anti-asialo-GM1 antibody. Metastasis progression was monitored by BLI for 160 days after cell inoculation. (d) Petal charts of metastasis incidence in specific organs after intracardiac inoculation of 2x104 KPad1 cells into 8-9 B6-albino mice or NSG mice. Metastasis progression was monitored by BLI for 60 days (B6-albino mice) or 28 days (NSG mice) after cell inoculation. (e) Flow cytometry analysis of Lineage–CD45+NKP46+ NK cells, CD45+CD3+CD4+, and CD45+CD3+CD8+ T cells in blood from B6-albino mice that were treated for 3 days with IgG control, anti-NK1.1, anti-CD4, or anti-CD8 antibodies. n = 3 mice per group. Mean ± s.e.m., two-sided unpaired t-test. (f) Metastasis-free survival Kaplan-Meier plots of NSG mice inoculated intracardially with KPad1 cells, or B6-albino mice inoculated intracardially with KPad1 cells or KP-482T1 cells, and treated with the indicated antibodies to deplete specific types of immune cells. 1 x 105 cells were inoculated per mouse. Antibody treatments started 12 days after inoculation. n = 8 (KPad1/control, KPad1/αCD4), 7 (KPad1/αNK1.1, KPad1/αCD8, KP-482T1), or 9 (NSG) mice per group, log-rank test. *, p = 0.03 (KPad1/αNK1.1 vs. KPad1/control), *, p = 0.0146 (KPad1/αCD8 vs. KPad1/control), **, p = 0.0094 (KPad1/αCD4 vs. KPad1/control), ***, p = 0.0002 (KP-482T1 vs. KPad1/control), ****, p < 0.0001 (KPad1/NSG vs. KPad1/control in B6-albino). (g) Gene set enrichment analysis (GSEA) showing pathways enriched in dormant H2087-LCC cells that were induced to proliferate in culture compared to cells from spontaneous metastatic outbreaks, analyzed from previous scRNA-seq data sets. (h–i) Metastasis-free survival of athymic mice (h) or B6-albino mice (i) intracardially inoculated with 2.5 x 105 H2087-LCC (h) or KPad1 cells (i), expressing a scrambled RNA control or various sgRNA pools. n = 9 (Scrambled), 10 (NK ligands and MHC class I), 12 (STING pathway), 10 (LPS and RNA-sensing pathways), or 11 (Interferon response, Complement pathway) mice per group (h); n = 7 (Scrambled, LPS and RNA-sensing pathways), 8 (Complement pathway), or 9 (other groups) mice per group (i). (j) BLI quantification of lung metastatic colonies after intravenous inoculation of 2.5 x 105 KPad1 cells expressing a scrambled control or different sgRNA pools in B6-albino mice. Tissues above the dotted line were harvested 57 days after cell inoculation, then subjected to sgRNA recovery and analysis. n = 9 (Additional MHC class I) or 10 (other groups) mice per group. (k–l) Gene rank based on the average fold enrichment of sgRNAs in multi-organ metastases from H2087-LCC (k) or KPad1 (l) cells. (m) Gene rank based on average fold change of sgRNAs enriched in the lung colonies formed after tail-vein inoculation of 2.5 x 105 KPad1 cells into B6-albino mice. For k-m, genes with average log2FC >0 are plotted and genes targeted by the top 10 enriched sgRNAs are listed.

Source Data

Extended Data Fig. 2 sgRNAs enriched in metastases of specific organs.

(a–b) Dot plots showing genes targeted by the enriched sgRNAs in metastases of the indicated organs after intracardiac inoculation of 2.5 x 105 H2087-LCC cells into athymic mice (a) or 2.5 x 105 KPad1 cells into B6-albino mice (b). Genes with average log2FC >0 are plotted.

Extended Data Fig. 3 STING in dormant and reactivated metastatic progenitors and progenies.

(a) As in Fig. 2a, representative IF images of single quiescent (Ki67low) and proliferative (Ki67high) cells during dormancy, and spontaneous outbreaks (SO) from H2087-LCC, stained for CCL5 IF (red), human vimentin (green), Ki67 IF (white), and DAPI (blue). The staining signal intensity of CCL5 in vimentin-positive cells was quantified and plotted (a.u., arbitrary units). Scale bar: 10 μm. n = 89 cells (Ki67low), 24 cells (Ki67high), or 45 regions (outbreaks), from 5 mice per group. Mean ± s.e.m, two-sided unpaired t-test. (b–c) Representative IF staining images of KPad1 cells (GFP, green) in brains of B6-albino mice that were intracardially inoculated with 1 x 105 KPad1 cells. Organs were harvested 25 days after inoculation to capture the dormant state, and 43–61 days after inoculation to capture spontaneous outbreaks. Tissue sections were stained for STING (b, red), CCL5 (c, red), Ki67 (b and c, white), and DAPI (b and c, blue), and the staining signal intensity of STING (b) and CCL5 (c) in GFP-positive cells was quantified and plotted (a.u., arbitrary units). Scale bar: 20 μm. n = 16 cells (Ki67low), 7 cells (Ki67high), or 22 lesions (outbreaks), from 4 mice per group in (b); n = 15 cells (Ki67low), 10 cells (Ki67high), or 33 lesions (outbreaks), from 4 mice per group in (c). Mean ± s.e.m, two-sided unpaired t-test. (d) Representative images of micrometastatic cells (cytokeratin AE1/AE3, green) in lymph nodes from stage II and stage III LUAD patients, stained for CCL5 IF (red), Ki67 (white), and DAPI (blue). The signal intensity of CCL5 in cytokeratin-positive cells was quantified and plotted. Scale bar: 20 μm. n = 24 (Ki67low) or 44 (Ki67high) regions, from 14 lymph nodes of 9 patients. Mean ± s.e.m., two-sided unpaired t-test. (e) Representative images of STING IHC intensity levels (0, none; 1, weak; 2, moderate; 3, strong) in patient-derived lung adenocarcinoma tissue samples. STING expression H-scores were calculated based on the intensity levels, representative of 2 independent experiments. Scale bar: 50 μm. (f–g) IF staining (f) and quantification (g) of CCL5 expression in patient-derived LUAD metastases compared to matched primary tumors. Tissue sections were stained for cytokeratin AE1/AE3 IF (green), CCL5 IF (red), and DAPI (blue), and the staining signal intensity of CCL5 in cytokeratin-positive areas was quantified and plotted (a.u., arbitrary units). Scale bar: 50 μm. n = 4 matched pairs, two-tailed paired t-test. (h) Expression of SOX transcription factors specifying early (SOX2) and late (SOX9) lung epithelial progenitor states, STING, canonical STING pathway targets, hallmark_interferon α response genes (GSEA), canonical and non-canonical NF-kB target genes (rows) across H2087-LCC single cells isolated from dormant metastases or spontaneous macrometastases in athymic mice, and cultured under growth-promoting conditions. STING pathway targets refers to the mean expression of the genes shown in Extended Data Fig. 4. For each gene, imputed expression was z-normalized across all cells. In the top row, cells (columns) are colored and labeled by source. n = 2245 cells isolated from 3 mice. (i) Violin plots showing imputed and z-normalized expression of STING in H2087-LCC cells from the data set used in (h). n = 2245 cells isolated from 3 mice. Two-sided Mann-Whitney U-test. (j) Expression of SOX transcription factors, STING, canonical STING pathway targets, hallmark interferon α response genes (GSEA), canonical and non-canonical NF-kB target genes (rows) across patient-derived metastatic tumor cells assigned to early or late-stage progenitor states. STING pathway targets refers to the mean expression of the genes shown in Extended Data Fig. 4. For each gene, imputed expression was z-normalized across all cells and smoothed using a 20-cell moving average window. Individual cells (columns) are ranked left to right by average lung epithelial development score. n = 991 cells isolated from 5 patients. (k) Violin plots showing imputed and z-normalized expression of STING across patient-derived tumor cells assigned to early or late-stage progenitor states from the data set used in (j). n = 991 cells isolated from 5 patients. Two-sided Mann-Whitney U-test. (l) Clustered heatmap showing expression of SOX2, SOX9, and STING in H2087-LCC cells isolated from metastases formed after NK cell depletion by anti-asialo-GM1 antibody treatment in athymic mice. For each gene, imputed expression was z-normalized across all cells. n =  6073 cells isolated from 5 mice. (m) qRT-PCR analysis of STING mRNA levels in H2087-LCC cell cultures derived from spontaneous outbreaks (SO) compared to those derived from outbreaks following depletion of NK cells. NK cells were depleted by treating mice with anti-asialo-GM1 antibody 30 days after cancer cell inoculation. n = 9 H2087-LCC cell lines from 4 mice after NK cell depletion or n = 17 cell lines from 8 mice with spontaneous outbreaks. Mean ± s.e.m., two-sided unpaired t-test. (n) IHC staining and quantification of STING expression (H-score) in H2087-LCC spontaneous outbreaks and outbreaks following NK cell depletion in multiple organs from athymic mice. Scale bar: 50 μm. n = 3 organs from 3 mice (NK depletion) or 7 organs from 3 mice (spontaneous). Mean ± s.e.m., two-sided unpaired t-test.

Source Data

Extended Data Fig. 4 Expression of canonical STING pathway targets from scRNA-seq datasets.

(a) Expression of SOX transcription factors specifying early (SOX2) and late (SOX9) lung epithelial progenitor states, STING and canonical STING pathway targets (rows) across H2087-LCC single cells isolated from dormant metastases, or spontaneous macrometastases in athymic nude mice, and cultured under growth-promoting conditions. STING pathway targets refers to the mean expression of the genes shown in the bottom heatmap panel. For each gene, imputed expression was z-normalized across all cells. In the top row, cells (columns) are colored and labeled by source. n = 2245 cells isolated from 3 mice. (b) Expression of SOX transcription factors, STING and canonical STING pathway targets (rows) across patient-derived metastatic tumor cells assigned to early or late-stage progenitor states. STING pathway targets refers to the mean expression of the genes shown in the bottom heatmap panel. For each gene, imputed expression was z-normalized across all cells and smoothed using a 20-cell moving average window. Individual cells (columns) are ranked left to right by average lung epithelial development score, as in Laughney et al. n = 991 cells isolated from 5 patients.

Extended Data Fig. 5 Perturbation of STING activity in human LUAD models.

(a) Western immunoblot analysis of STING and β-actin in WT and STING knockout H2087-LCC cells, representative of 2 independent experiments. (b–c) Immunoblotting (b) and qRT-PCR analyses (c) of STING expression in parental H2087-LCC cells and the spontaneous outbreak derivatives SO1 and SO2. Mean ± s.e.m, representative of 2 independent experiments. In (c), each dot represents a technical replicate of the assay. (d) qRT-PCR analysis of IFNB1 expression after cGAMP treatment of H2087-LCC, SO1, and SO2 cells. Mean ± s.e.m, representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (e) Western immunoblot analysis of STING (endogenous STING and HA-tagged STING) and β-actin in H2087-LCC-SO cells inducibly expressing STING-HA under doxycycline (Dox) treatment for 24 h. Representative of 2 independent experiments. (f) Metastasis-free survival plots of athymic mice inoculated intracardially with 1 x 105 H2087-LCC-SO cells. Cells were transduced with a vector control or a Dox-inducible STING expression vector. Dox treatment started 7 days after cell inoculation. n = 13 (Control, STING), 10 (Control+Dox), 11 (STING+Dox) mice per group, log-rank test. (g) qRT-PCR analysis of STING mRNA levels in human primary bronchial epithelial cells, H2087, A549, and H2030 LUAD cell lines. Mean ± s.e.m, representative of 3 independent experiments. Each dot represents a technical replicate of the assay. (h–i) qRT-PCR analysis of IFNB1 mRNA expression in human primary bronchial epithelial cells and lung adenocarcinoma cell lines treated with cGAMP (h) or poly(I:C) (i). Mean ± s.e.m, representative of 3 independent experiments. Each dot represents a technical replicate of the assay. (j) BLI and quantification of metastases formed by H2030-BrM cells inducibly expressing activated STING-V155M, starting the day after intracardiac inoculation of 1 x 105 cells in athymic mice. Metastases were quantified 21 days after inoculation. n = 9 mice per group. Mean ± s.e.m., two-sided Mann-Whitney U-test. For gel source data, see Supplemental Fig. 1.

Source Data

Extended Data Fig. 6 STING activity in mouse lung adenocarcinoma cells.

(a-b) qRT-PCR analysis of Sting (a) and Cxcl10 (b) mRNA levels after cGAMP treatment in KPad1 and KP-482T1 cells. Mean ± s.e.m, representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (c) Western immunoblotting of STING and β-actin in parental and Sting knockout KPad1 cells. Representative of 2 independent experiments. For gel source data, see Supplemental Fig. 1. (d) RFP-positive WT KPad1 cells and GFP-positive Sting KO KPad1 cells were mixed at the indicated ratios and intracardially inoculated (1 x 105 cells) in B6-albino mice. Metastases-bearing organs were harvested 4-17 weeks after inoculation and the percentage of GFP-positive cells and RFP-positive cells was determined by flow cytometry. n = 9 (1:1, 9:1) or 5 (3:1) lesions from 3-5 mice per group. Mean ± s.e.m. (e) Percentage of EdU positive cells of WT or Sting knockout KPad1 cells incubated with EdU for 2 h. n = 3 per group. Mean ± s.e.m. (f) Percentage of EdU positive cells in KP-482T1 Tet-On Sting cultures treated with Dox for 24 h and then incubated with EdU for 2 h. n = 3 per group. Mean ± s.e.m. (g–h) BLI signal intensity at the indicated time points after intracardiac inoculation of 1 x 105 WT or Sting knockout KPad1 cells (g) or KP-482T1 cells with induced overexpression of STING (h) in B6-albino mice. n = 16 (WT) or 15 (KO) mice (g); n = 7 (control) or 6 (Dox) mice (h). Mean ± s.e.m. (i) Heatmap representation of cytokine array analysis of culture supernatant from KP-482T1 cells transduced with a vector control or a Sting overexpression vector. n = 3 for each condition.

Source Data

Extended Data Fig. 7 STING knockout and overexpression effects on growth and differentiation of metastatic progenitors.

(a) Percentage of EdU positive cells of WT or STING knockout H2087-LCC cells incubated with EdU for 2 h. n = 3 per group. Mean ± s.e.m. (b) Percentage of EdU positive cells in H2087-LCC-SO Tet-On STING or H2030-BrM Tet-On STINGV155M cultures treated with Dox for 24 h, and then incubated with EdU for 2 h. n = 3 per group. Mean ± s.e.m. (c-d) BLI signal intensity at the indicated time points after intracardiac inoculation of 1 x 105 WT or STING knockout H2087-LCC cells (c) or H2030-BrM cells with Dox-induced overexpression of STINGV155M (d) in athymic mice. n = 7 (WT, KO1) or 6 (KO2) mice per group (c); n = 9 (7 days) or 7 (other groups) mice per group (d). Mean ± s.e.m. (e) IF staining analysis showing percentage of SOX2high and SOX9high cells in spontaneous metastases formed after intracardiac inoculation of 1 x 105 WT or STING knockout (KO) H2087-LCC cells in athymic mice. Organs were harvested 12 weeks after inoculation. n = 10 lesions (WT) or 23 lesions (STING KO). Mean ± s.e.m. (f) IF staining analysis showing percentage of SOX2high and SOX9high cells in metastases formed after intracardiac inoculation of 1 x 105 H2087-LCC-SO cells inducibly overexpressing STING in athymic mice. Organs were harvested 7–13 weeks after inoculation for the control cells and 18 weeks after inoculation for the STING overexpressing cells. n = 48 images from 5 mice (control) or 13 images from 3 mice (Dox). Mean ± s.e.m.

Source Data

Extended Data Fig. 8 Cancer cell STING increases NK and T cell levels in metastases.

(a) Schematic of flow cytometry or immunofluorescence analysis of immune cells in bone metastasis. (b) Flow cytometry analysis and quantification of CD45+ leukocytes, CD45+CD19−TCRβ−XCR1+CD11c+ cDC1 cells, CD45+NK1.1+TCRβ−CD49b+NKp46+ NK cells, CD45+TCRβ+NK1.1−CD8+ T cells, and CD45+TCRβ+NK1.1−CD4+ T cells in KP-482T1 metastasis-bearing femurs after Dox-induced expression of STING for 2 days or 7 days. Cell numbers per gram of femur tissue were counted and normalized to control (-Dox). Metastasis-bearing femurs were collected 2 weeks after intracardiac inoculation of 2 x 104 KP-482T1 cells in B6-albino mice. n = 7 mice per group. Mean ± s.e.m., two-sided unpaired t-test. p values comparing each Dox treatment group with control (−Dox). (c–f) Percentage of NK cells degranulating (CD107a+) (c) or producing IFNγ (d), and percentage of CD44+CD8+ T cells producing IFNγ (e) or TNF (f), isolated from KP-482T1 metastasis-bearing femurs after Dox-induced expression of STING for 2 days or 7 days, and then cultured ex vivo with phorbol 12-myristate 13-acetate (PMA) and ionomycin for 4h. n = 5 (+Dox 7 days) or 6 (other groups) mice per group. Mean ± s.e.m. (g) Schematic of the NK cell-mediated killing assay, and the percentage of WT or STING KO H2087-LCC cells killed by incubation with naïve NK cells for 4h at the indicated effector:target ratios. n = 3 per group. Mean ± s.e.m. (h) Schematic of the trans-well migration assay, and the number of NK cells migrated into cell culture media conditioned by WT or STING knockout H2087-LCC cells. n = 3 per group. Mean ± s.e.m., two-sided unpaired t-test.

Source Data

Extended Data Fig. 9 STING locus regulation during metastatic progression.

(a) Gene track view for H3K27ac, H3K4me1, and H3K4me3 ChIP-Seq tags at the STING locus in H2087-LCC, spontaneous outbreak derivative H2087-LCC-SO1, and H2030 cells. (b) ChIP-PCR analysis of DNMT3B binding to the STING promoter or 3′ enhancer regions in parental H2087-LCC, H2087-LCC-SO1, H2087-LCC-SO2, and in A549 and H2030 cells. Mean ± s.e.m., representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (c) qRT-PCR analysis of STING mRNA levels in H2030 and A549 cells after a 3-day treatment with 100nM 5-aza-2′deoxycytidine (5-azadC) in culture. Mean ± s.e.m., representative of 3 independent experiments. Each dot represents a technical replicate of the assay. (d) Schematic of targeted bisulfite sequencing analysis of the STING locus in metastatic cells of interest.

Source Data

Extended Data Fig. 10 TGF-β mediated suppression of STING expression.

(a) Growth rate of H2087-LCC cells treated with TGF-β or CDK4/6 inhibitor palbociclib for the indicated times. n = 4. Mean ± s.e.m., two-way ANOVA analysis. (b) qRT-PCR analysis of STING mRNA levels in H2087-LCC cells treated with TGF-β or palbociclib for 7 days. Mean ± s.e.m., representative of 3 independent experiments. Each dot represents a technical replicate of the assay. (c) qRT-PCR analysis of IFNB1 and CCL5 expression in WT or STING knockout H2087-LCC cells treated with TGF-β for 3 days. Mean ± s.e.m., representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (d) qRT-PCR analysis of cGAS mRNA levels in H2087-LCC cells treated with TGF-β for 7 days. Mean ± s.e.m., representative of 3 independent experiments. Each dot represents a technical replicate of the assay. (e) ELISA analysis of cGAMP levels in H2087-LCC cells treated with TGF-β for 5 days. n = 3 per group. Mean ± s.e.m. (f) Gene track view of H3K27ac, H3K4me1, and H3K4me3 ChIP-Seq tags at the STING locus in H2087-LCC cells treated with TGF-β for 4 days. (g) PCR based quantitation of methylated STING promoter and 3′ enhancer sequences in MeDIP samples from H2087-LCC cells that were treated with TGF-β for the indicated times. Mean ± s.e.m., representative of 3 independent experiments. Each dot represents a technical replicate of the assay. (h) Schematic of the TGF-β and SMAD-dependent transcriptional reporter. SBE: Smad Binding Element. mCMV: minimal CMV promoter. TRE: Tetracycline-Responsive promoter Element. (i) Representative IF staining images of H2087-LCC cells (human vimentin, green) expressing SMAD-responsive mCherry reporter in the lungs of athymic mice intravenously inoculated with 1x105 cells. Organs were harvested 8 weeks after inoculation. Disseminated cancer cells were present as single quiescent (Ki67low) or proliferative cells (Ki67high, white). Representative of 2 independent experiments. Scale bar: 20 μm. (j) qRT-PCR analysis of SMAD7, SNAI1 and STING expression in H2087-LCC cells treated with TGF-β or no additions for 2 h or 96 h, respectively. Mean ± s.e.m., representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (k) Representative IHC images (left) and quantification (right) of the proportion of H2087-LCC single cells, small clusters, micrometastases, and macrometastases in the lungs of NSG mice 7 weeks after intravenous injection of 1x105 cells. Scale bar: 50 μm. n = 102 (WT) or 33 (KO) single cells, 17 (WT) or 12 (KO) small clusters, 31 (WT) or 71 (KO) micrometastases, and 5 (WT) or 9 (KO) macrometastases. (l) IF staining of human vimentin (green), DAPI (blue), and CCL5 (red), in lung metastases generated 7 weeks after intravenous inoculation of 1x105 WT or TGFBR2 knockout H2087-LCC cells in NSG mice. The IF staining intensity in vimentin-positive areas was quantified. Scale bar: 50 μm. n = 41 (WT) or 55 (KO) lesions from 5 mice. Mean ± s.e.m., two-sided unpaired t-test.

Source Data

Extended Data Fig. 11 Immune cell dependence of STING agonist-mediated suppression of metastasis reactivation.

(a) Rationale for experimental design. (b-c) qRT-PCR analysis of CXCL10 and CCL5 mRNA levels in WT or STING knockout KPad1 (b) or H2087-LCC (c) cells treated with 33 μM MSA-2 for 4 h. Mean ± s.e.m., representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (d–e) Treatment was performed as in (b, c) but with 10 μM (KPad1) or 50 μM (H2087-LCC) ADU-S100. Mean ± s.e.m., representative of 2 independent experiments. Each dot represents a technical replicate of the assay. (f-j) Metastasis-free survival plots of B6-albino mice intracardially inoculated with 2.5x105 KPad1 cells, treated with both MSA-2 and IgG control (f, n = 10 mice) or individual antibodies to deplete NK cells (g, n = 10 mice for vehicle or 8 mice for MSA-2), CD4+ T cells (h, n = 10 mice), CD8+ T cells (i, n = 10 mice), or a combination of these antibodies (j, n = 10 mice for vehicle or 9 mice for MSA-2). Mice were administered antibodies (200 μg/mouse) once weekly for 3 weeks starting 6 days after cell inoculation, and vehicle or MSA-2 (50 mg/kg of body weight) once weekly for 2 weeks starting 9 days after cell inoculation. Log-rank test. (k) Metastasis-free survival plots of B6-albino mice intracardially inoculated with 2.5 x 105 KPad1 cells pre-treated with 33 μM MSA-2 for 24h before inoculation. n = 10 mice per group. (l) Metastasis-free survival plots of C57BL/6J mice intravenously inoculated with 2.5 x 105 WT or Sting knockout KPad1 cells and treated with vehicle or ADU-S100 (1.25 mg/kg of body weight) once weekly by intratracheal delivery until the study endpoint. ADU-S100 treatment started 5 days after cell inoculation. n = 15 mice (control) or 8 mice (ADU-S100). Log-rank test. (m) Quantification of WT or STING knockout H2087-LCC cell numbers in lungs from athymic mice treated with vehicle or ADU-S100 (6.25 mg/kg of body weight) once weekly for 4 weeks by intratracheal delivery. ADU-S100 treatment started 1 week after intravenous inoculation of 1 x 105 cells. Lungs were harvested 5 weeks after inoculation. n = 5 mice per group. Mean ± s.e.m., two-sided unpaired t-test.

Source Data

Supplementary information

Supplementary Figures

This file contains two supplementary figures. Supplementary Fig. 1. Raw images of uncropped gels. Supplementary Fig. 2. Example of gating strategy for flow cytometry analysis of cDC1 cells, NK cells and T cells.

Reporting Summary

Peer Review File

Supplementary Table 1

GSEA analysis showing significantly enriched hallmarks in proliferative H2087-LCC cells compared to immune-evasive metastatic outbreaks, analysed from scRNA seq data (Laughney et al., 2020).

Supplementary Table 2

sgRNA sequences for CRISPR screens of human H2087-LCC.

Supplementary Table 3

sgRNA sequences for CRISPR screens of mouse KPad1.

Supplementary Table 4

Metastatic potential to the indicated organs from H2087-LCC and KPad1 cells expressing the individual sgRNA pools.

Supplementary Table 5

CRISPR screen score in H2087-LCC and KPad1.

Supplementary Table 6

Gene signatures.

Supplementary Table 7

CpG sites in STING promoter and 3′ enhancer.

Supplementary Table 8

Primers for CRISPR screen.

Source data

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, J., Sánchez-Rivera, F.J., Wang, Z. et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature 616, 806–813 (2023). https://doi.org/10.1038/s41586-023-05880-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41586-023-05880-5

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer